Drug-maker Wockhardt said that its business in the US , for the three months ended December 31, recorded a 45 per cent growth over the corresponding period last year.
Growth in this market was driven by niche products that were launched last year, the company said.
During the quarter under review, the company also received three product approvals. Wockhardt’s international business contributed 83 per cent to its total revenues during the quarter.
Its business in the UK recorded a growth of 19 per cent compared to the corresponding quarter of the previous year, in an otherwise stagnant market, the company said. The Irish market recorded a growth of 3 per cent for the period under review.
India business grew 14 per cent and the emerging markets business grew 18 per cent compared to the corresponding quarter last year, the company said.
Wockhardt shares were down over two per cent on the BSE, at Rs 1,728, on Thursday.